Bladder and bowel dysfunction in Parkinson's disease

Area of Science:

• Neurology
• Gastroenterology
• Urology

Background:

• Parkinson's disease (PD) commonly presents with non-motor symptoms, including bladder and bowel dysfunction.
• These pelvic autonomic disorders, unlike motor symptoms, often show resistance to levodopa treatment.
• Understanding the distinct pathophysiology is crucial for effective management and differential diagnosis.

Purpose of the Study:

• To elucidate the distinct pathophysiological mechanisms underlying bladder and bowel dysfunction in Parkinson's disease.
• To explore the role of central and peripheral nervous system alterations in these non-motor symptoms.
• To highlight the potential of targeted therapies for improving patient outcomes.

Main Methods:

• Review of current literature on the neuroanatomy and neurophysiology of bladder and bowel control in Parkinson's disease.
• Analysis of the differential impact of dopamine pathways on the central nervous system and enteric nervous system.
• Comparison of the pathophysiology of pelvic organ dysfunction in PD versus other neurodegenerative diseases like multiple system atrophy.

Main Results:

• Bladder dysfunction (urgency/frequency) in PD is primarily linked to altered dopamine-basal ganglia circuits affecting the central nervous system's control over the micturition reflex.
• Bowel dysfunction (constipation, slow transit) in PD is mainly attributed to peripheral enteric pathology involving the dopamine-enteric nervous system, impairing peristalsis.
• Brain pathology may also contribute to bowel issues like weak strain and paradoxical anal contraction.
• Pathophysiological differences exist between PD and multiple system atrophy, aiding differential diagnosis.

Conclusions:

• Bladder and bowel dysfunction in Parkinson's disease arise from distinct central and peripheral neurological mechanisms.
• Targeted pharmacological interventions, such as anticholinergic agents for bladder issues and dietary/pharmacological approaches for bowel problems, offer therapeutic potential.
• Effective management of these non-motor symptoms can enhance patients' quality of life, improve levodopa absorption, and prevent gastrointestinal emergencies.